title: Disease recurrence following cetuximab completion and declining a gastrectomy: what next to manage Ménétriers disease?
abstract: Ménétriers disease is a rare mucosal hyperproliferative disorder of the stomach, however, the evidence for long-term care remains limited, especially if a gastrectomy is declined. We present a case of 25-year-old Caucasian woman with a history of end-stage renal failure (ESRF) who experienced worsening symptoms of abdominal pain, haematemesis and abdominal swelling, with her serum albumin dropping to 20 g/L and haemoglobin to 4.9 g/dL. Endoscopy showed markedly hyperplastic gastric folds consistent with Ménétriers disease, confirmed histologically by gland dilation and gastric pit expansion. Intravenous cetuximab was prescribed for 12 months, with clinical, biochemical and endoscopic improvement. However, 5 weeks post cetuximab completion, there was relapse to 50% gastric coverage with Ménétriers. A discussion around gastrectomy was rejected by the patient. This is the first report of relapsing Ménétriers disease in a female patient with ESRF; we suggest that long-term cetuximab should be considered if a gastrectomy is declined.
authors.affiliation: Birmingham Heartlands Hospital, Birmingham, West Midlands, UK.
authors.forename: Mitesh
authors.initials: M
authors.lastname: Patel
authors.affiliation: Department of Gastroenterology, Birmingham Heartlands Hospital, Birmingham, UK.
authors.forename: Marcus
authors.initials: M
authors.lastname: Mottershead
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001706:Biopsy; D000068818:Cetuximab; D003937:Diagnosis, Differential; D016099:Endoscopy, Gastrointestinal; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy; D005753:Gastric Mucosa / Q000473:pathology; D005758:Gastritis, Hypertrophic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab